tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hyperlipidemias D006949 73 associated lipids
Hyperparathyroidism, Secondary D006962 4 associated lipids
Hypersensitivity D006967 22 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Hypersensitivity, Immediate D006969 14 associated lipids
Hypertension D006973 115 associated lipids
Hypertension, Portal D006975 12 associated lipids
Hypertension, Renal D006977 9 associated lipids
Hypoglycemia D007003 13 associated lipids
Hypotension D007022 41 associated lipids
Hypothermia D007035 19 associated lipids
Ileal Neoplasms D007078 2 associated lipids
Immunoblastic Lymphadenopathy D007119 2 associated lipids
Immunologic Deficiency Syndromes D007153 8 associated lipids
Immune System Diseases D007154 3 associated lipids
Impetigo D007169 3 associated lipids
Erectile Dysfunction D007172 19 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Incontinentia Pigmenti D007184 2 associated lipids
Infection D007239 6 associated lipids
Inflammation D007249 119 associated lipids
Influenza, Human D007251 11 associated lipids
Insulin Resistance D007333 99 associated lipids
Intertrigo D007402 1 associated lipids
Intestinal Atresia D007409 3 associated lipids
Intestinal Fistula D007412 1 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Intussusception D007443 1 associated lipids
Ischemia D007511 18 associated lipids
Kaposi Varicelliform Eruption D007617 1 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Keloid D007627 12 associated lipids
Kidney Diseases D007674 29 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Vulvar Lichen Sclerosus D007724 1 associated lipids
Labyrinthitis D007762 2 associated lipids
Leg Injuries D007869 2 associated lipids
Legionellosis D007876 3 associated lipids
Lentigo D007911 1 associated lipids
Leukemia D007938 74 associated lipids
Leukemia P388 D007941 43 associated lipids
Leukemia, Myeloid D007951 52 associated lipids
Leukocytosis D007964 9 associated lipids
Leukoplakia D007971 1 associated lipids
Leukoplakia, Oral D007972 1 associated lipids
Lichen Planus D008010 3 associated lipids
Listeriosis D008088 12 associated lipids
Liver Abscess D008100 6 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Mathieu C et al. Potential role of 1,25(OH)2 vitamin D3 as a dose-reducing agent for cyclosporine and FK 506. 1994 Transplant. Proc. pmid:7527950
Wennberg L et al. Immunosuppression with leflunomide and cyclosporine prevents pig-to-rat islet xenograft rejection. 1995 Transplant. Proc. pmid:8539967
Murase N et al. Effect of FK 506 and antiproliferative agents for heart and liver xenotransplantation from hamster to rat. 1993 Transplant. Proc. pmid:7679817
Ueki M et al. Functional and morphologic characterization of renal subcapsular islet isografts in rats treated with FK 506. 1994 Transplant. Proc. pmid:7513469
Loinaz C et al. A single-centre experience with cyclosporine microemulsion versus tacrolimus in 100 randomized liver transplant recipients: midterm efficacy and safety. 2001 Nov-Dec Transplant. Proc. pmid:11750472
Ito T et al. The mechanism of tolerance induced by a perioperative injection of bone marrow cells and a brief course of FK 506. 1991 Transplant. Proc. pmid:1703716
Rostaing L et al. Early posttransplantation renal hemodynamics in FK 506-treated kidney recipients with or without prior induction therapy. 1998 Transplant. Proc. pmid:9636519
Braun F et al. Primary tacrolimus immunosuppression in kidney recipients considered "higher immunological risk". 2000 Transplant. Proc. pmid:11119893
Kamińska D et al. Significant infections after hand transplantation in a Polish population. 2014 Transplant. Proc. pmid:25380943
Marin-Gomez LM et al. Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study. 2009 Jul-Aug Transplant. Proc. pmid:19715867
Montejo M et al. Prophylactic therapy with valgancyclovir in high-risk (cytomegalovirus D+/R-) liver transplant recipients: a single-center experience. 2009 Jul-Aug Transplant. Proc. pmid:19715869
Aktürk S et al. Pregnancy After Kidney Transplantation: Outcomes, Tacrolimus Doses, and Trough Levels. 2015 Transplant. Proc. pmid:26093738
Shoji T et al. Long-term acceptance of porcine pulmonary allografts without chronic rejection. 2005 Jan-Feb Transplant. Proc. pmid:15808551
Yamamoto S et al. FK778 controls acute rejection after rat liver allotransplantation showing positive interaction with FK506. 2005 Jan-Feb Transplant. Proc. pmid:15808570
Ortiz de Urbina J et al. Advagraf de novo in liver transplantation: a single-center experience. 2011 Transplant. Proc. pmid:21486583
Pérez MJ et al. Cardiovascular risk factors after liver transplantation: analysis of related factors. 2011 Transplant. Proc. pmid:21486587
Lee KK et al. Successful orthotopic small bowel transplantation with short-term FK 506 immunosuppressive therapy. 1990 Transplant. Proc. pmid:1689908
Ueda Y et al. Induction of graft acceptance after dog kidney or liver transplantation. 1990 Transplant. Proc. pmid:1689909
Reyes J et al. Nutritional management of intestinal transplant recipients. 1993 Transplant. Proc. pmid:7680149
Farghali H et al. Effect of FK 506 chronic administration on bromosulphthalein hepatic excretion in rats. 1991 Transplant. Proc. pmid:1721283
Pirenne J et al. Addition of the colon to small bowel grafts causes lethal graft-versus-host disease in FK 506-treated pigs. 1996 Transplant. Proc. pmid:8623447
Liu WT et al. In vitro generation of tacrolimus metabolites and their detection in whole blood. 1998 Transplant. Proc. pmid:9636590
Jiang H and Kobayashi M Differences between cyclosporin A and tacrolimus in organ transplantation. 1999 Transplant. Proc. pmid:10455942
Sekido H et al. Successful conversion from cyclosporine to tacrolimus for immunosuppression. 2000 Transplant. Proc. pmid:11120096
Kliem V et al. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation. 1999 Transplant. Proc. pmid:10576041
Friemann S et al. Conversion to tacrolimus in hyperlipidemic patients. 1999 Transplant. Proc. pmid:10576042
Gonzalez-Molina M et al. Mycophenolate mofetil and tacrolimus reduce mortality after deceased donor kidney transplantation. 2012 Transplant. Proc. pmid:23146459
Yeung S et al. Primary immunosuppression with tacrolimus and low-dose mycophenolate mofetil in renal transplant recipients. 2004 Transplant. Proc. pmid:15518754
Kawaoka T et al. Two patients treated with simeprevir plus pegylated-interferon and ribavirin triple therapy for recurrent hepatitis C after living donor liver transplantation: case report. 2015 Transplant. Proc. pmid:25891736
Metcalfe S et al. FK 506 and cyclosporine A: early effects on activation and gene induction in mouse spleen cells. 1990 Transplant. Proc. pmid:1697107
Miyazawa H et al. Mechanisms of hamster kidney graft rejection in the rat. 1994 Transplant. Proc. pmid:7518111
Abouljoud MS et al. Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group. 1995 Transplant. Proc. pmid:7533360
Wiesner RH et al. Early cellular rejection treated with high-dose intravenous corticosteroid therapy is associated with a decrease in the incidence of steroid-resistant rejection and graft failure from rejection. 1993 Transplant. Proc. pmid:7682352
Morozumi K et al. Diagnosis of chronic rejection using peritubular and glomerular capillary lesions. 1996 Transplant. Proc. pmid:8644331
Bäckman L et al. Whole-blood and plasma levels of FK 506 after liver transplantation: results from the US Multicenter Trial. FK506 Multicenter Study Group. 1995 Transplant. Proc. pmid:7533361
McCarthy SA et al. Effects of FK 506 and cyclosporine on T-cell tolerance: inhibition of a "protective" mechanism that regulates activation-induced apoptosis in developing thymocytes. 1991 Transplant. Proc. pmid:1721314
Zeevi A et al. Comparative in vitro studies on the immunosuppressive activities of mycophenolic acid, bredinin, FK 506, cyclosporine, and rapamycin. 1991 Transplant. Proc. pmid:1721315
Uchida H et al. Experimental intestinal transplantation using mouse fetal intestine in the rat: combination effect of FK 506 with cyclophosphamide. 1999 Transplant. Proc. pmid:10578297
Tullius SG et al. ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results. 2003 Transplant. Proc. pmid:14529854
Manu MA et al. Tacrolimus rescue for resistant rejection, chronic rejection, and immunoglobulin A nephropathy of renal allografts under primary cyclosporine A immunosuppression. 1999 Transplant. Proc. pmid:10578313
Jacob DA et al. Liver transplantation for primary biliary cirrhosis: influence of primary immunosuppression on survival. 2005 Transplant. Proc. pmid:15919432
Ciancio G et al. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center. Transplant. Proc. pmid:27569936
Chuang JP et al. Does immunosuppressive pharmacotherapy affect isoagglutinin titers? 2008 Transplant. Proc. pmid:18929836
Tannuri AC et al. Effects of immunosuppressants on hepatocyte cell mitosis during liver regeneration in growing animal models of partial hepatectomy. 2008 Transplant. Proc. pmid:18589165
Lladó L et al. Prospective study of a tacrolimus-based quadruple immunosuppressive regimen: evaluation of safety and efficacy. 2002 Transplant. Proc. pmid:12176468
Jiang H et al. Immunosuppressive effects of FK 506 on rat renal allograft survival, in comparison with cyclosporine. 1995 Transplant. Proc. pmid:7533413
Fleck PR et al. Tacrolimus use in kidney-pancreas recipients is associated with less acute renal dysfunction than cyclosporine. 1998 Transplant. Proc. pmid:9865299
Nakamura K et al. The lymphocytotoxic crossmatch in liver transplantation: a clinicopathologic analysis. 1991 Transplant. Proc. pmid:1721346
Krämer BK et al. Cardiovascular risk estimates and risk factors in renal transplant recipients. 2005 Transplant. Proc. pmid:15919488
Wlodarczyk Z et al. Lipid metabolism in renal transplant patients receiving tacrolimus/sirolimus combination therapy. 2005 Transplant. Proc. pmid:15919489
Regazzi MB et al. Pharmacokinetics of FK506 and mycophenolic acid in experimental and clinical intestinal transplantation. 1997 Transplant. Proc. pmid:9142302
Moro JA et al. Randomized prospective study of the evolution of renal function depending on the anticalcineurin used. 2008 Transplant. Proc. pmid:19010143
Fukuhara N et al. Long-term outcome of tacrolimus in cadaveric kidney transplantation from non-heart-beating donors. 2002 Transplant. Proc. pmid:12176492
Gruttadauria S et al. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. 2005 Jul-Aug Transplant. Proc. pmid:16182762
Iaria G et al. Switch to tacrolimus for cyclosporine-induced gynecomastia in liver transplant recipients. 2005 Jul-Aug Transplant. Proc. pmid:16182769
Gojowy D et al. High Frequency of Arterial Hypertension in Patients After Liver Transplantation. 2016 Transplant. Proc. pmid:27496479
Ota K Living donor kidney transplantation in Japan. 1994 Transplant. Proc. pmid:7520622
Takahara S et al. Monitoring of FK 506 blood levels in kidney transplant recipients. 1994 Transplant. Proc. pmid:7520623
Watanabe K et al. Prolongation effect of FK506 on the survival of 3-day preserved kidney allografts in dogs. 1998 Transplant. Proc. pmid:9838579
Wagner K et al. Effect of FK 506 on excretion of urinary enzymes in rats. 1991 Transplant. Proc. pmid:1721379
Warty V et al. Distribution of FK 506 in plasma lipoproteins in transplant patients. 1991 Transplant. Proc. pmid:1703363
Molmenti E et al. Noncompliance after pediatric liver transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083164
Wada Y et al. Expression of the transcriptional factor egr-1/BTEB2 in cardiac xenograft vascular remodeling. 2000 Transplant. Proc. pmid:10936371
Li W et al. High-dose cellular IL-10 exacerbates rejection and reverses effects of cyclosporine and tacrolimus in Mouse cardiac transplantation. 1997 Feb-Mar Transplant. Proc. pmid:9123209
Sharma A et al. Incidence of glucose metabolic abnormalities in Indian living renal allograft recipients on tacrolimus-based triple drug immunosuppression. 2008 Transplant. Proc. pmid:18790252
Schumacher G et al. Neurologic symptoms improve in patients with Wilson's disease despite immunosuppression. 1996 Transplant. Proc. pmid:8962200
Beaunoyer M et al. Low-dose tacrolimus, trough-monitored mycophenolate mofetil, and planned steroid withdrawal for cadaveric kidney transplantation: a single center experience. 2002 Transplant. Proc. pmid:12176540
Gu B et al. Exploration of Fecal Microbiota Transplantation in the Treatment of Refractory Diarrhea After Renal Transplantation. 2018 Transplant. Proc. pmid:29880353
Lee H et al. Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience. 2018 Transplant. Proc. pmid:29880348
Gasser M et al. Putative regulatory function of alloreactive Th2 cells in tolerant recipients after small bowel transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11266759
Tai J et al. In vivo and in vitro effect of FK 506 on rat Leydig cell function. 1991 Transplant. Proc. pmid:1721409
Sato Y et al. FK 506 suppresses class II antigen expression in regenerating livers following partial hepatectomy in the rat. 1992 Transplant. Proc. pmid:1379761
Jiang H et al. Inhibition of IL-10 by FK 506 may be responsible for overcoming ongoing allograft rejection in the rat. 1999 Feb-Mar Transplant. Proc. pmid:10083538
Alessiani M et al. Correlations between functional changes and different grades of acute rejection in swine small bowel allografts. 2000 Transplant. Proc. pmid:10995933
Hoshino Y et al. FTY720, a novel immunosuppressant, shows a synergistic effect in combination with FK 506 in rat allograft models. 1999 Feb-Mar Transplant. Proc. pmid:10083547
Kato Y et al. Epidermal growth factor enhances the intestinal adaptation of small bowel allografts in the postoperative period. 2000 Transplant. Proc. pmid:10995935
Kahan BD High variability of drug exposure: a biopharmaceutic risk factor for chronic rejection. 1998 Transplant. Proc. pmid:9723224
Keown PA and Primmett DR Cyclosporine: the principal immunosuppressant for renal transplantation. 1998 Transplant. Proc. pmid:9723252
Mendes J et al. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. 2009 Transplant. Proc. pmid:19376366
Weir MR Optimizing early de novo immunosuppression with sirolimus. 2008 Transplant. Proc. pmid:19100903
Khwaja K et al. Pancreas transplantation in cross-match-positive recipients using cyclosporine- or tacrolimus-based immunosuppression. 2002 Transplant. Proc. pmid:12176621
Beckebaum S et al. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study. 2004 Transplant. Proc. pmid:15621120
Rigotti P et al. Antilymphocyte induction is no longer necessary in simultaneous pancreas and kidney transplantation. 2002 Transplant. Proc. pmid:12176623
Rintala JM et al. The effect of leflunomide analogue FK778 on development of chronic rat renal allograft rejection and transforming growth factor-BETA expression. 2006 Transplant. Proc. pmid:17175234
Del Castillo D Analysis of primary and recurrent rejection following renal transplantation in a large, comparative, multicentre trial. 2001 Feb-Mar Transplant. Proc. pmid:11267283
Yokomise H et al. Immunosuppressive effects of FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721442
McCauley J et al. Renal transplantation under FK 506 in African-Americans: early experience. 1993 Transplant. Proc. pmid:7689270
Fukuoka N et al. Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation. 2010 Transplant. Proc. pmid:20832577
Ochiai T et al. Histopathologic studies in renal transplant recipient dogs receiving treatment with FK-506. 1987 Transplant. Proc. pmid:2445085
Xu M et al. FTY720 compares with FK 506 as rescue therapy in rat heterotopic cardiac transplantation. 1998 Transplant. Proc. pmid:9723447
Maroun T et al. Rejection therapy with tacrolimus in renal transplantation: preliminary results of a collaborative multicenter study in 45 patients. Groupe Cooperatif de Transplantation D'ile de France (GCIF). 1998 Transplant. Proc. pmid:9745576
Velioglu A et al. Association of BK Virus Titers With Lymphocyte Count in Renal Transplant Patients. 2015 Transplant. Proc. pmid:26093733
Ito Y et al. Complete replacement of tracheal epithelia by the host promotes spontaneous acceptance of orthotopic tracheal allografts in rats. 2004 Transplant. Proc. pmid:15561264
Owen ER et al. Peripheral nerve regeneration in human hand transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267484
Molmenti EP et al. Incidence, management, and outcome of posttransplant lymphoproliferative disease in pediatric liver transplant recipients. 2001 Feb-Mar Transplant. Proc. pmid:11267487
Barak S et al. Alveolar bone height in patients after liver transplantation. 2000 Transplant. Proc. pmid:10856558
Stempfle HU et al. Rapid trabecular bone loss after cardiac transplantation using FK506 (tacrolimus)-based immunosuppression. 1998 Transplant. Proc. pmid:9636459
Marcus N et al. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients. 1998 Transplant. Proc. pmid:9636460
Wojciechowski D et al. Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients. 2017 Transplant. Proc. pmid:28923623
Girman P et al. Similar early complication rate in simultaneous pancreas and kidney recipients on tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus immunosuppressive regimens. 2010 Jul-Aug Transplant. Proc. pmid:20692391